The Relative Strength (RS) Rating for Disc Medicine jumped into a new percentile Wednesday, with an increase from 74 to 81.
Looking For The Best Stocks To Buy And Watch? Start Here
This unique rating tracks technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the best stocks often have an RS Rating north of 80 as they begin their biggest runs.
While it's not currently an ideal time to jump in, see if the stock is able to form a chart pattern and break out.
The company posted 0% earnings growth in the latest quarterly report, while sales growth came in at 0%. The next quarterly results are expected on or around Aug. 8.
Disc Medicine earns the No. 129 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Anbio Biotechnology and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
